Skip to main content
OpenTrials
Completed

NCT Number: NCT02532244

Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases

The goal of this study is to establish a genetic registry of patients with early-onset motor neuron and neuromuscular diseases. The investigators will collect samples from patients with a motor neuron or a neuromuscular disorder and their family members. The samples to be collected will be obtained using minimally invasive (whole blood) means. The research team will then extract high quality genomic DNA or RNA from these samples and use it to identify and confirm novel gene mutations and to identify genes which regulate the severity of motor neuron/neuromuscular diseases.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Diseases affecting the motor unit--which is composed of the motor neuron, its myelin sheath and its innervated muscle fibers--are a diverse, heterogeneous group having heterogeneous clinical presentations and genetic causes. Many of these disorders have a inherited component. In some cases, the genetics underlying a given neuromuscular/motor neuron disease, like spinal muscular atrophy (SMA) or Duchenne muscular dystrophy, are well characterized. There are, however, disorders whose genetic basis has yet to be determined or genetically characterized diseases which harbor novel mutations. The purpose of this genetic registry is to catalogue early-onset motor neuron and neuromuscular disorders and to determine their genetic bases. With samples obtained from this registry, the investigators will be able to provide a genetic diagnosis for a specific neuromuscular/motor neuron disease which will lead to better care for those patients affected by these diseases.

Many of these disorders have a wide spectrum of phenotypic variability. For example, the severity of SMA is quite variable even though it is caused by the loss of a single gene, i.e. survival motor neuron 1 (SMN1). The number of copies of the duplicated gene survival motor neuron 2 (SMN2) dictates phenotypic severity in SMA. In this study, the research team will also identify potential modifiers of phenotypic severity for specific disorders like SMA and Charcot-Marie-Tooth (CMT) disease. With the identification of novel modifier genes, the investigators will be able to more accurately predict disease outcomes and the investigators will also have novel targets for the development of therapeutic agents for these diseases.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of motor neuron/neuromuscular disease confirmed by neurologist
  • Be seen by one of the study investigators

Exclusion criteria

  • not seen by one of the study investigators

Treatment and study plan

Sample collection

Other

collection of blood

Primary outcomes

  1. genetic diagnosis

    Time frame: up to 2 years

    The genetic basis for the subject's condition will be verified/determined by Sanger sequencing of DNA sample

Secondary outcomes

  1. SMN1 copy number

    Time frame: up to 2 years

    The number of copies of the SMN1 gene will be determined using array digital polymerase chain reaction (PCR).

  2. SMN2 copy number

    Time frame: up to 2 years

    The number of copies of the SMN2 gene will be determined using array digital PCR.

  3. target gene mRNA levels

    Time frame: up to 2 years

    The relative levels of the disease gene-specific messenger ribonucleic acid (mRNA) will be measured using quantitative PCR.

  4. target gene protein levels

    Time frame: up to 2 years

    The relative amounts of the disease-gene-specific protein will be measured using immunoblot.

Sponsors and collaborators

Lead sponsor

Nemours Children's Clinic

Other

Registry information

Important dates

Study start
2015
Primary completion
2024
Study completion
2024
First posted
Aug 25, 2015
Registry last updated
Dec 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.